XTL Biopharmaceuticals Ltd Cash Flow-to-Debt Ratio
XTL Biopharmaceuticals Ltd cash flow-to-debt ratio. XTL Biopharmaceuticals Ltd (H2K2) has a Cash Flow-to-Debt Ratio of -0.52x as of December 2024, meaning its operating cash flow of €-1.62 Million could theoretically repay -1% of its total liabilities (€3.12 Million) in one year. Check XTL Biopharmaceuticals Ltd (H2K2) cash earnings ratio to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of XTL Biopharmaceuticals Ltd (2016–2024)
Cash flow-to-debt ratio of XTL Biopharmaceuticals Ltd from 2016 to 2024. Historical debt coverage capacity for XTL Biopharmaceuticals Ltd across 9 annual periods. Also explore XTL Biopharmaceuticals Ltd (H2K2) net asset momentum to track the company's year-over-year net asset growth rate.
XTL Biopharmaceuticals Ltd Cash Flow-to-Debt Ratio by Year (2016–2024)
XTL Biopharmaceuticals Ltd cash flow-to-debt ratio by year from 2016 to 2024. Year-by-year debt coverage analysis for XTL Biopharmaceuticals Ltd. For the full cash flow conversion analysis, see XTL Biopharmaceuticals Ltd (H2K2) cash flow conversion.
| Year | CF-to-Debt Ratio | Operating CF (EUR) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -0.52x | €-1.62 Million | €3.12 Million | ▲ +84.9% |
| 2023 | -3.43x | €-707.00K | €206.00K | ▲ +28.8% |
| 2022 | -4.82x | €-901.00K | €187.00K | ▼ -490.2% |
| 2021 | -0.82x | €-1.05 Million | €1.28 Million | ▲ +75.6% |
| 2020 | -3.35x | €-850.00K | €254.00K | ▲ +14.5% |
| 2019 | -3.91x | €-908.00K | €232.00K | ▼ -21.3% |
| 2018 | -3.23x | €-816.00K | €253.00K | ▼ -750.6% |
| 2017 | -0.38x | €-1.12 Million | €2.97 Million | ▲ +92.8% |
| 2016 | -5.25x | €-1.73 Million | €330.00K | — |